deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02120157

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions Graft Survival HLA-mismatched Bone Marrow Transplantation Myeloablative Conditioning Transplantation, Bone Marrow
Interventions Busulfan Cyclophosphamide Mycophenolate mofetil TBI Tacrolimus Unmanipulated Bone Marrow
Updated 15 times since 2017 Last updated: Nov 23, 2021 Started: Jul 2, 2015 Primary completion: Jun 15, 2018 Completion: Oct 1, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Graft Survival and HLA-mismatched Bone Marrow Transplantation and is currently completed. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins leads this study, which shows 15 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Apr 2018 · 7 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~May 2019 · 11 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2021 — Dec 2021 [monthly]

    Completed PHASE2

▶ Show 10 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. May 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Jun 2018 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Sep 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

  7. May 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  8. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE2

  9. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations